No abstract

utilities for pazopanib and placebo were from PALETTE. Lacking a connected evidence network, estimates of relative effectiveness for trabectedin and ifosfamide were from an unadjusted indirect treatment comparison vs. pazopanib. Costs were from NHS reference costs and other published sources. RESULTS: Compared with placebo, pazopanib is estimated to increase QALYs by 0.130 and costs by £8,072; the incremental cost effectiveness ratio (ICER) for pazopanib vs. placebo is estimated to be £63k/QALY gained. For most parameters, the ICER changed Ͻ30% with ϩ/Ϫ50% changes in the parameter value. Compared with trabectedin and ifosfamide, pazopanib provides equal or more QALYs at a lower cost. CONCLUSIONS: From a UK health care system perspective, pazopanib may not be cost-effective vs. placebo in patients with advanced/metastatic STS based on criteria typically used to evaluate therapies in the UK. Pazopanib may be cost-effective vs. trabectedin and ifosfamide, although there is substantial uncertainty associated with these comparisons. OBJECTIVES:Eurtact trial was the first randomized phase III trial evaluating efficacy and safety of erlotinib vs chemotherapy in the first-line treatment of EGFR mutϩ Caucasian patients. This trial showed an increase in the median PFS of 4,5 months with erlotinib vs chemotherapy. Based on this study, we aimed to assess the cost-effectiveness of erlotinib versus platinum based chemotherapy in the first-line treatment of advanced NSCLC patients with activating EGFR mutations. METHODS: A health economic cost-effectiveness analysis was developed incorporating a Markov model simulating the evolution of a cohort of advanced NSCLC patients with activating EGFR mutations. Three health states were included: Progression Free Survival (PFS), Progression and Death. The time horizon was 7 years. Outcomes were life years gained (LYG). Resource utilization related to each health state was estimated by a Spanish Expert Panel. Cost were expressed in € 2012 and include drug and administration costs, and drug-related adverse events management cost. This analysis was performed taking into account the Spanish National Health System's perspective. Patient data on progression-free and overall survival were obtained from the EURTAC study. Probabilistic sensitivity analyses were conducted to incorporate parameter uncertainties. RESULTS: Erlotinib treated patients achieved a mean of 2.161 LYG compared to 1.555 LYG in patients receiving chemotherapy. Total mean treatment cost with erlotinib and chemotherapy was €22,458 and €5,335 respectively. The incremental cost-effectiveness ratio (ICER) per LYG was €28,261. Since erlotinib treatment is prolonged until disease progression and chemotherapy is stopped at 4 cycles, treatment duration is one of the cost-driver of the model. CONCLUSIONS: Erlotinib treatment of NSCLC patients with activating EGFR mutations is associated with an increased life expectancy and is a costeffective therapeutic option in Spain. OBJECTIVES:Hormone refractory prostate cancer has generally poor ...

No abstract

Objectives: Systemic Lupus Erythematosus (SLE) is an autoimmune disease, characterized by periods of remissions and flares, with significant clinical and economic burden. The primary study objective was to estimate the 1-year direct medical cost for adult patients with active, autoantibody-positive SLE in Greece. MethOds: This is a national, multi-centre, retrospective study. Data were abstracted from patient records in 6 hospital centers specialized in SLE management. Starting with the patient with the most recent visit, patients with consecutive visits (backwards in time) were considered for inclusion, provided they met specific criteria. In order to estimate costs per disease severity, a stratification criterion was applied. Patient data were collected for a 1-year period starting from the inclusion date (January -September 2011) and moving forward. Data included patient characteristics and health care resource utilization. In addition, all SLE patients fulfilling the inclusion criteria and followed-up in the participating centers during a 3-month retrospective period were recorded. For cost calculation, official 2013 list prices were used. Results: 215 patients (30% severe according to the stratification criterion) were included in the study. Mean direct medical costs were estimated at € 1,225 for patients with non-severe and at € 3,741 for patients with severe active SLE. Laboratory and imaging tests, medicines, physicians' visits, and hospitalization costs represented 10.5%, 51.7%, 1.2%, 36.5% of mean cost respectively. Costs were statistically significantly higher for severe SLE patients. The total number of patients visiting the participating clinical sites during a 3-month period was 318 (19% with severe SLE). The weighted mean annual direct medical cost of SLE in Greece was estimated at € 1,703. cOnclusiOns: Direct medical cost of SLE in Greece is significant, especially for patients with severe disease. An estimation of indirect costs would provide a comprehensive picture of the societal burden of the disease.Objectives: Immune thrombocytopenia (ITP) is characterized by isolated thrombocytopenia with no underlying cause. It manifests clinically as mucocutaneous bleeding caused by decreased platelets. Recently, two thrombopoietin receptor-agonists have emerged as an important therapeutic options: romiplostim and eltrombopag. Since these medications have different mode of administration, safety and efficacy profiles, the present study was carried out in an attempt to investigate which drug would be more cost-effective in the Brazilian setting. The objective was to perform an economic analysis evaluating the cost per response of romiplostim versus eltrombopag in adult patients with chronic ITP and refractory to other treatments as corticosteroids and immunoglobulins in Brazil health care private system. MethOds: Two economic analyses were performed in order to study the use of romiplostim and eltrombopag for the treatment of adults with chronic refractory ITP, based on annual treatment costs and cost per ...

No abstract